We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Cytovale

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-movin... read more Featured Products: More products

Download Mobile App





Cytovale Demonstrates 8-Minute Sepsis Diagnostic Test

By LabMedica International staff writers
Posted on 01 Aug 2024

Cytovale (South San Francisco, CA, USA) is exhibiting at the ADLM 2024 Clinical Lab Expo where the company is demonstrating its FDA-cleared IntelliSep sepsis test, which processes samples in around 8 minutes. More...

Visitors to the Cytovale booth can also see the Cytovale System in action. With cutting-edge host response technology, the IntelliSep sepsis test along with the Cytovale System provides laboratory professionals with sepsis risk stratification results in ~8 minutes, enabling teams in the Emergency Department (ED) to make timely, life-saving decisions. The IntelliSep test is the only test of its kind that is U.S. Food and Drug Administration (FDA)-cleared for detecting sepsis in an adult population that presents with signs and symptoms of infection to the ED. The test provides critical new information about immune activation and sepsis risk stratification through a simple blood draw in about 8 minutes.

A recent large-scale study confirmed that Cytovale's IntelliSep test accurately predicts sepsis risk and severity, and aids in appropriate triage and treatment pathways in the ED. The study analyzed 1,002 patients and evaluated the accuracy of IntelliSep to rapidly diagnose patients with sepsis and help clinicians expedite appropriate care. IntelliSep demonstrated impressive 'rule-out' performance related to sepsis, with a negative predictive value of 97.5%, which, combined with the 0.0% sepsis mortality rate for patients with low-risk scores, may allow the care team to explore alternative diagnoses in low-risk patients. The test showed similar 'rule-in' performance to other critical ED tests, with a positive predictive value of 55%. The Cytovale System which can be seen in action at the show interrogates thousands of cells per second to rapidly assess host immune state and identify disease signatures. A simple workflow with minimal hands-on time provides clinicians with actionable information in under 10 minutes to aid in diagnosis and inform treatment.

Related Links:
Cytovale


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.